Motco Sells 1,000 Shares of Stryker Co. (NYSE:SYK)

Motco cut its stake in shares of Stryker Co. (NYSE:SYK) by 58.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 709 shares of the medical technology company’s stock after selling 1,000 shares during the period. Motco’s holdings in Stryker were worth $255,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SYK. Arkadios Wealth Advisors increased its position in shares of Stryker by 23.0% in the third quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock worth $265,000 after purchasing an additional 137 shares during the last quarter. Strategic Blueprint LLC increased its position in shares of Stryker by 5.8% in the third quarter. Strategic Blueprint LLC now owns 1,426 shares of the medical technology company’s stock worth $515,000 after purchasing an additional 78 shares during the last quarter. Mutual Advisors LLC increased its position in shares of Stryker by 9.0% in the third quarter. Mutual Advisors LLC now owns 5,562 shares of the medical technology company’s stock worth $2,002,000 after purchasing an additional 457 shares during the last quarter. SteelPeak Wealth LLC increased its position in shares of Stryker by 7.3% in the third quarter. SteelPeak Wealth LLC now owns 796 shares of the medical technology company’s stock worth $288,000 after purchasing an additional 54 shares during the last quarter. Finally, US Bancorp DE increased its position in shares of Stryker by 1.3% in the third quarter. US Bancorp DE now owns 181,849 shares of the medical technology company’s stock worth $65,697,000 after purchasing an additional 2,301 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on SYK shares. Needham & Company LLC restated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group upped their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Citigroup restated a “buy” rating and issued a $450.00 price objective on shares of Stryker in a research report on Wednesday. Finally, JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $422.15.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.6 %

Shares of Stryker stock opened at $386.55 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The stock has a market capitalization of $147.50 billion, a price-to-earnings ratio of 49.81, a P/E/G ratio of 2.93 and a beta of 0.96. The company’s 50 day moving average price is $380.50 and its 200-day moving average price is $370.92.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the business earned $3.46 EPS. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.